Diffuse Cutaneous Systemic Sclerosis Clinical Trial
Official title:
A Phase 2 Study to Evaluate Subcutaneous Abatacept vs. Placebo in Diffuse Cutaneous Systemic Sclerosis- a Double-blind, Placebo-controlled, Randomized Controlled Trial.
The study hypothesis is that SC abatacept is safe and shows evidence of efficacy (improvement in modified Rodnan score [mRSS]) in patients with diffuse cutaneous systemic sclerosis (dcScc) compared to matching placebo.
This study is a randomized placebo-controlled double-blind phase 2 trial of patients with dcSSc. Eligible participants will be randomized in a 1:1 ratio to either 125 mg SC abatacept or matching placebo, stratified by duration of dcSSc disease duration (<18 months vs >18 to </=36 months). Study participants will be treated for 12 months on double-blind study medication, followed by an additional 24 weeks of open-label SC abatacept therapy. 86 patients will be randomized in approximately 35 centers in the US, Canada and Europe, with the goal of analyzing 74 participants. The investigators study will test whether abatacept is statistically superior to placebo in reducing the MRSS at month 12 and explore the ability of abatacept to prevent or reverse progression in patients with early disease duration and lower MRSS scores, and reverse established disease in patients with longer disease duration and higher MRSS scores. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03222492 -
Brentuximab Vedotin for Systemic Sclerosis
|
Phase 1/Phase 2 | |
| Completed |
NCT04137224 -
Safety and Pharmacokinetics of IgPro20 and IgPro10 in Adults With Systemic Sclerosis (SSc)
|
Phase 2 | |
| Not yet recruiting |
NCT04986605 -
Extracorporeal Photopheresis in Early Diffuse Cutaneous Systemic Sclerosis
|
Phase 2 | |
| Completed |
NCT02503644 -
Proof-of-concept Trial of IVA337 in Diffuse Cutaneous Systemic Sclerosis
|
Phase 2 | |
| Enrolling by invitation |
NCT05626751 -
An Open-label Extension Trial of HZNP-HZN-825-301 in Adult Participants With Diffuse Cutaneous Systemic Sclerosis (Diffuse Cutaneous SSc)
|
Phase 2 | |
| Withdrawn |
NCT05098145 -
A Safety and Efficacy Study of FCR001 in Adults With Rapidly Progressive Diffuse Cutaneous Systemic Sclerosis
|
Phase 1/Phase 2 | |
| Terminated |
NCT04478994 -
A Study With TEPEZZA in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
|
Phase 1 | |
| Completed |
NCT03198689 -
Brentuximab Vedotin in Early Diffuse Cutaneous Systemic Sclerosis
|
Phase 2 | |
| Terminated |
NCT04680975 -
Efficacy and Safety of Belumosudil in Subjects With Diffuse Cutaneous Systemic Sclerosis
|
Phase 2 | |
| Completed |
NCT00433186 -
Mycophenolate Mofetil in Systemic Sclerosis
|
Phase 1 | |
| Terminated |
NCT03919799 -
KD025 in Subjects With Diffuse Cutaneous Systemic Sclerosis
|
Phase 2 | |
| Not yet recruiting |
NCT06152172 -
CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101
|
Phase 1 | |
| Suspended |
NCT04166552 -
Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Diffuse Cutaneous Systemic Sclerosis
|
Phase 2 | |
| Not yet recruiting |
NCT06375005 -
Efficacy and Safety of Telitacicept in the Treatment of Systemic Sclerosis
|
Phase 2 | |
| Recruiting |
NCT05270668 -
Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
|
Phase 2 | |
| Recruiting |
NCT05168215 -
Effectiveness of Bosentan Therapy in Patients With Systemic scleRosis and Progressive Digital ulcEr Disease.
|
||
| Completed |
NCT04440592 -
Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic Sclerosis
|
Phase 2 | |
| Recruiting |
NCT05149768 -
Open Label Extension Study of Brentuximab Vedotin in Early dcSSc
|
Phase 2 | |
| Withdrawn |
NCT04138485 -
Efficacy and Safety of IgPro10 in Adults With Systemic Sclerosis (SSc)
|
Phase 2 | |
| Terminated |
NCT03398837 -
Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis
|
Phase 3 |